Mouse Anti-EFEMP2 Recombinant Antibody (1C2) (CBMAB-0045-YC)

Name: Mouse Anti-EFEMP2 Recombinant Antibody (1C2)
SKU: CBMAB-0045-YC
Rating: 5 (1 reviews)

See all EFEMP2 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

1C2

Application

WB, ELISA

Immunogen

Full-length recombinant EFEMP2.

Host Species

Mouse

Specificity

Human, Mouse, Rat

Antibody Isotype

IgG2a, κ

Clonality

Monoclonal Antibody

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS

Preservative

None

Concentration

Batch dependent

Storage

Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

EGF-containing fibulin-like extracellular matrix protein 2

Introduction

EGF-containing fibulin-like extracellular matrix protein 2 (EFEMP2) is a protein that in humans is encoded by the EFEMP2 gene. EFEMP2 (also known as fibulin-4) contains four EGF2 domains and six calcium-binding EGF2 domains. This gene is widely expressed in a range of adult and fetal tissues. EFEMP2 has been shown to interact with P53, which may be in implicated in functions as diverse as blood coagulation, activation of complement and determination of cell fate during development.

Entrez Gene ID

30008

UniProt ID

O95967

Alternative Names

EGF Containing Fibulin-Like Extracellular Matrix Protein 2; Fibulin 4; Fibulin-4; FIBL-4; FBLN4; EGF-Containing Fibulin-Like Extracellular Matrix Protein 2; Mutant P53 Binding Protein 1; Protein UPH1; ARCL1B; MBP1; UPH1

Research Area

Plays a crucial role in elastic fiber formation in tissue, and in the formation of ultrastructural connections between elastic laminae and smooth muscle cells in the aorta, therefore participates in terminal differentiation and maturation of smooth muscle cell (SMC) and in the mechanical properties and wall integrity maintenance of the aorta (PubMed:27339457).

In addition, is involved in the control of collagen fibril assembly in tissue throught proteolytic activation of LOX leading to cross- linking of collagen and elastin (By similarity).

Also promotes ELN coacervation and participates in the deposition of ELN coacervates on to microfibrils but also regulates ELN cross- linking through LOX interaction (PubMed:18973305, PubMed:19570982).

Moreover adheres to the cells through heparin binding in a calcium-dependent manner and regulates vascularlar smooth muscle cells proliferation through angiotensin signaling (PubMed:23782690).

Biological Process

Aorta development Source: UniProtKB
Aorta smooth muscle tissue morphogenesis Source: UniProtKB
Elastic fiber assembly Source: UniProtKB
Negative regulation of vascular associated smooth muscle cell proliferation Source: UniProtKB
Positive regulation of aortic smooth muscle cell differentiation Source: UniProtKB
Positive regulation of collagen fibril organization Source: UniProtKB
Positive regulation of smooth muscle cell-matrix adhesion Source: UniProtKB
Regulation of collagen fibril organization Source: UniProtKB
Vascular associated smooth muscle cell development Source: UniProtKB

Cellular Location

Extracellular matrix; Basement membrane. Localizes on the microfibrils surrounding ELN cores.

Involvement in disease

Cutis laxa, autosomal recessive, 1B (ARCL1B):
A connective tissue disorder characterized by loose, hyperextensible skin with decreased resilience and elasticity leading to a premature aged appearance. Face, hands, feet, joints, and torso may be differentially affected. The clinical spectrum of autosomal recessive cutis laxa is highly heterogeneous with respect to organ involvement and severity. ARCL1B features include emphysema, lethal pulmonary artery occlusion, aortic aneurysm, cardiopulmonary insufficiency, birth fractures, arachnodactyly, and fragility of blood vessels.

PTM

N-glycosylated; contains mostly complex-type glycans (PubMed:27339457, PubMed:23782690). Not O-glycosylated (PubMed:27339457).
Cleaved by ELANE; produces a 50-55 kDa fragment (PubMed:27339457). Cleaved by MMP2 and MMP9; produces several fragments (PubMed:27339457).

Li, N., Ji, G. X., & Yang, Z. Y. (2022). EFEMP2 increases the invasion ability of cervical cancer cells by promoting EMT via the Raf/MEK/ERK signaling pathway. Neoplasma, 220117N74-220117N74.

Zhou, Q., Chen, S., Lu, M., Luo, Y., Wang, G., Xiao, Y., ... & Wang, X. (2022). Erratum: EFEMP2 suppresses epithelial-mesenchymal transition via Wnt/β-catenin signaling pathway in human bladder cancer: Erratum. International Journal of Biological Sciences, 18(9), 3798-3799.

Shen, Y., Zhou, T., Liu, X., Liu, Y., Li, Y., Zeng, D., ... & Zhang, M. (2021). Sevoflurane-induced miR-211-5p promotes neuronal apoptosis by inhibiting Efemp2. ASN neuro, 13, 17590914211035036.

Loeys, B., De Paepe, A., & Urban, Z. (2020). EFEMP2-related cutis laxa.

Song, L., Li, X. X., Liu, X. Y., Wang, Z., Yu, Y., Shi, M., ... & He, X. P. (2020). EFEMP2 suppresses the invasion of lung cancer cells by inhibiting epithelial-mesenchymal transition (EMT) and down-regulating MMPs. OncoTargets and therapy, 13, 1375.

Huang, L., Wang, Z., Chang, Y., Wang, K., Kang, X., Huang, R., ... & Hu, H. (2020). EFEMP2 indicates assembly of M0 macrophage and more malignant phenotypes of glioma. Aging (Albany NY), 12(9), 8397.

Zhou, Q., Chen, S., Lu, M., Luo, Y., Wang, G., Xiao, Y., ... & Wang, X. (2019). EFEMP2 suppresses epithelial-mesenchymal transition via Wnt/β-catenin signaling pathway in human bladder cancer. International journal of biological sciences, 15(10), 2139.

Kang, N., Zhou, J., Xu, J., Zhou, D., & Shi, W. (2019). EFEMP2 Inhibits Breast Cancer Invasion And Metastasis In Vitro And In Vivo. OncoTargets and therapy, 12, 8915.

Zuo, T., Shan, J., Liu, Y., Xie, R., Yu, X., & Wu, C. (2018). EFEMP2 mediates GALNT14-dependent breast cancer cell invasion. Translational oncology, 11(2), 346-352.

Letard, P., Schepers, D., Albuisson, J., Bruneval, P., Spaggiari, E., Van de Beek, G., ... & Guimiot, F. (2018). Severe phenotype of cutis laxa type 1B with antenatal signs due to a novel homozygous nonsense mutation in EFEMP2. Molecular Syndromology, 9(4), 190-196.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-EFEMP2 Recombinant Antibody (1C2)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Mouse Anti-EFEMP2 Recombinant Antibody (1E8) (CAT#: V2LY-0425-LY1488)

Mouse Anti-EFEMP2 Recombinant Antibody (CBXF-1704) (CAT#: CBMAB-F3239-CQ)

Mouse Anti-EFEMP2 Recombinant Antibody (2C8) (CAT#: V2LY-0425-LY1489)

Mouse Anti-EFEMP2 Recombinant Antibody (AG63) (CAT#: V2LY-0524-LY41)

Mouse Anti-EFEMP2 Recombinant Antibody (E0821) (CAT#: V2LY-0425-LY1486)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry